- Home
- PMF vs AVR Comparison
PMF vs AVR Comparison
Compare PMF & AVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMF
- AVR
- Stock Information
- Founded
- PMF 2001
- AVR 1999
- Country
- PMF United States
- AVR Australia
- Employees
- PMF N/A
- AVR N/A
- Industry
- PMF Finance/Investors Services
- AVR
- Sector
- PMF Finance
- AVR
- Exchange
- PMF Nasdaq
- AVR NYSE
- Market Cap
- PMF 207.9M
- AVR 241.5M
- IPO Year
- PMF N/A
- AVR 2024
- Fundamental
- Price
- PMF $8.23
- AVR $4.21
- Analyst Decision
- PMF
- AVR Strong Buy
- Analyst Count
- PMF 0
- AVR 4
- Target Price
- PMF N/A
- AVR $16.50
- AVG Volume (30 Days)
- PMF 61.3K
- AVR 255.8K
- Earning Date
- PMF 01-01-0001
- AVR 05-20-2025
- Dividend Yield
- PMF 5.36%
- AVR N/A
- EPS Growth
- PMF N/A
- AVR N/A
- EPS
- PMF N/A
- AVR N/A
- Revenue
- PMF N/A
- AVR $2,703,000.00
- Revenue This Year
- PMF N/A
- AVR $29.52
- Revenue Next Year
- PMF N/A
- AVR $204.83
- P/E Ratio
- PMF N/A
- AVR N/A
- Revenue Growth
- PMF N/A
- AVR N/A
- 52 Week Low
- PMF $7.69
- AVR $2.34
- 52 Week High
- PMF $10.56
- AVR $8.79
- Technical
- Relative Strength Index (RSI)
- PMF 48.66
- AVR N/A
- Support Level
- PMF $8.17
- AVR N/A
- Resistance Level
- PMF $8.34
- AVR N/A
- Average True Range (ATR)
- PMF 0.11
- AVR 0.00
- MACD
- PMF 0.06
- AVR 0.00
- Stochastic Oscillator
- PMF 79.63
- AVR 0.00
About PMF PIMCO Municipal Income Fund
PIMCO Municipal Income Fund is a closed-end management investment company. Its primary investment objective is to seek to provide current income exempt from federal income tax. The fund invests a majority of its net assets in municipal bonds that pay interest that is exempt from federal income tax.
About AVR ANTERIS TECHNOLOGIES GLOBAL CORP
Anteris Technologies Global Corp. is a structural heart company committed to discovering, developing and commercializing medical devices designed to improve the quality of life for patients with aortic stenosis. Its product, the DurAVR THV system, represents a product opportunity in a new THV class of single-piece heart valves, for the treatment of aortic stenosis. Its DurAVR THV system consists of a single-piece, biomimetic valve made with its proprietary ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold.